|
|
Murabutide |
|
Vaxjo ID |
475 |
|
Vaccine Adjuvant Name |
Murabutide |
|
Adjuvant VO ID |
VO_0005752
|
|
Description |
synthetic derivative of muramyl dipeptide (MDP) that induces Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
USA |
|
Host Species for Testing |
Mouse |
|
Components |
bacterial cell wall peptidoglycan component that is recognized by NOD2 receptors |
|
Function |
Type: peptide vaccine adjuvant. Target Receptor: nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Induces Th1-biased immune profile. recognition by NOD2 receptors |
|
Safety |
less pyrogenic and toxic than MDP, causes little to no inflammation |
| References |
Feinen et al., 2014: Feinen B, Petrovsky N, Verma A, Merkel TJ. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clinical and vaccine immunology : CVI. 2014; 21(4); 580-586. [PubMed: 24554695].
Telzak et al., 1986: Telzak E, Wolff SM, Dinarello CA, Conlon T, el Kholy A, Bahr GM, Choay JP, Morin A, Chedid L. Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine. The Journal of infectious diseases. 1986; 153(3); 628-633. [PubMed: 3950444].
|
|
